Treatment with phenelzine (an LSD1 inhibitor) reduced the activity of H3K4 and H3K9 nuclear demethylase that resulted in the activation of the transcription and expression of M1-like markers both in vitro and in vivo in the mouse model of triple negative breast cancer. The gene discussed is KDM1A; the disease is triple-negative breast carcinoma.